A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects
Phase of Trial: Phase III
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Desmopressin (Primary)
- Indications Nocturia
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 05 Oct 2017 Status changed from recruiting to completed.
- 28 Sep 2016 New trial record
- 25 Sep 2016 Status changed from not yet recruiting to recruiting.